by Sean Ungerer | Sep 11, 2024 | Healthcare
Following the trading statement on 30 August, the FY 24A results held few surprises as AfroCentric had already indicated a mixed performance across its segments: Revenue growth was muted at +1% YoY, while operating profit rose by +2%, leading to a slight margin...
by Sean Ungerer | Aug 30, 2024 | Healthcare
Key points from the statement: – Stable medical scheme administration: This segment, which contributed 54% to FY 23A operating profits, has remained steady with growth in various public and private schemes. – Pharmaceutical Cluster challenges: The...
by Sean Ungerer | Mar 16, 2023 | Healthcare
H1 23A results snapshot: Revenue growth was subdued, up 1% y/y (+1% h/h), driven by the Group Admin business (+2% y/y), while Healthcare Retail revenue was broadly flat. EBITDA was down 9% y/y (-18% h/h), with profitability in Healthcare Retail under the most...
by Sean Ungerer | Oct 6, 2022 | Healthcare
FY 22A results snapshot: Revenue increased by 8% y/y, driven by the Services Business, while Retail printed low single digit growth. EBITDA was flat y/y, where the Services business margin came under pressure, while the Retail business saw robust margin expansion....
by Sean Ungerer | Mar 18, 2022 | Healthcare
H1 22A results snapshot: Revenue +10% y/y (+3% h/h); EBITDA +5% y/y (-12% h/h), which meant the EBITDA margin moderated by 64bps y/y to 12.5%. Normalized HEPS (N.HEPS) and DPS were stable y/y at ZAr 26.51 and ZAr 17 (4% dividend yield), respectively. Shares in issue...
by Sean Ungerer | Oct 15, 2021 | Healthcare
Execution of a clearly defined strategy has seen AfroCentric Investment Corporation (ACT) deliver a robust performance in the last ten years: Revenue and adjusted EBITDA have increased by a CAGR of 20% and 15%, respectively. This has translated into diluted HEPS and...
